ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024
Evaluation of Neurodegenerative Disorders with Amyloid-β, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Thai Guideline for Nuclear Medicine Investigations of Neurocognitive Disorders: Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and Thai Medical Physicist Society Collaboration.Diagnostics (Basel, Switzerland) · 2024Guideline
- Stage-stratified benefits of AI-radiomics PET in early Alzheimer's disease: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Genetic Determinants of Tau-PET Imaging in Alzheimer's Disease: A Narrative Review of Genome-Wide and Candidate-Gene Studies.Journal of imaging · 2026Review
- Review
- MR-Guided PET Denoising and Resolution Enhancement Improves Visual Interpretation and Preserves Quantitative Behavior Across Amyloid Tracers.medRxiv : the preprint server for health sciences · 2026Article
- Comparison betweenQuantitative imaging in medicine and surgery · 2026Article
- Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- AI-Driven Breast Cancer Diagnosis: A Systematic Review of Imaging Modalities, Deep Learning, and Explainability.Cancers · 2026Review
- Limited predictive value of preoperative nigrosome integrity for motor outcomes in Parkinson's disease deep brain stimulation.NPJ Parkinson's disease · 2025Article
- Artificial Intelligence in PET Imaging for Alzheimer's Disease: A Narrative Review.Brain sciences · 2025Review
- AI-powered model for accurate prediction of MCI-to-AD progression.Acta pharmaceutica Sinica. B · 2025Article
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- The role of nuclear medicine in neurodegenerative diseases: a narrative review.American journal of neurodegenerative disease · 2025Review
- Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges.Frontiers in medicine · 2024Review
- Variable Aβ tracer uptake in hyperostosis frontalis interna: implications for brain Aβ PET/CT interpretation.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- From amyloid PET to plasma biomarkers: A multimodal imaging framework for early diagnosis and staging of Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiamyloid therapies for Alzheimer disease recently entered clinical practice, making imaging biomarkers for Alzheimer disease even more relevant to guiding patient management. Amyloid and tau PET are valuable tools that can provide objective evidence of Alzheimer pathophysiology in living patients and will increasingly be used to complement
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.